Products for Research Use Only
RegisterLogin

Tigecycline

CAT: 0804-HY-B0117-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0117-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[1]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[2].
CAS Number
220620-09-7
Product Name Alternative
GAR-936
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Autophagy; Bacterial
Type
Reference compound
Related Pathways
Anti-infection; Autophagy
Applications
COVID-19-immunoregulation
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Tigecycline.html
Purity
99.95
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=C(NC(CNC(C)(C)C)=O)C=C4N(C)C)N
Molecular Formula
C29H39N5O8
Molecular Weight
585.65
Precautions
H302, H315, H319, H335
References & Citations
[1]Jitkova Y, et al. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014 May 28;9 (5) :e95281.|[2]Falagas ME, et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Adv Ther (Weinh) . 2024 Jan 12.|Anim Dis. 2021;1 (1) :26.|Ann Clin Microbiol Antimicrob. 2024 Aug 20;23 (1) :73.|Antimicrob Agents Chemother. 2019 May 24;63 (6) . pii: e00470-19.|Antimicrob Agents Chemother. 2023 Feb 16;67 (2) :e0145922.|Antimicrob Agents Chemother. 2024 Mar 6;68 (3) :e0112023.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Authorea. 2025 Sep 17.|Biomed Pharmacother. 2023 Dec 31:169:115856.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell. 2025 May 15;188 (10) :2757-2777.e22.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Cureus. 2024 Dec 1;16 (12) :e74917.|EBioMedicine. 2022 Apr;78:103943.|Infect Drug Resist. 2020 Jul 28;13:2617-2629.|Infect Drug Resist. 2021 Jun 30;14:2499-2507.|Infect Drug Resist. 2023 Apr 17:16:2271-2279.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|Int J Antimicrob Agents. 2025 Jun 9:107551.|J Antibiot (Tokyo) . 2022 Aug;75 (8) :463-471.|J Antimicrob Chemother. 2025 Apr 10:dkaf105.|J Appl Microbiol. 2025 Apr 17:lxaf093.|Microb Pathog. 2020 Dec;149:104502.|Microbiol Spectr. 2023 Feb 14;11 (1) :e0323822.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0071823.|Microbiol Spectr. 2025 Mar 19:e0134424.|Microorganisms. 2024 Mar 13;12 (3) :575.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Nat Commun. 2024 Jun 28;15 (1) :5481.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 29.|SLAS Discov. 2020 Sep;25 (8) :895-905.|Vet Microbiol. 2024 May:292:110046.|World J Microbiol Biotechnol. 2024 Jun 6;40 (8) :233.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.

Alternative Products

CatalogName
A5226-5Tigecycline

Popular Products